enGene (Nasdaq: ENGN) is a clinical-stage biotechnology company mainstreaming non-viral genetic medicines that can be delivered locally to the site of disease—starting with non-muscle invasive bladder cancer (NMIBC) and expanding beyond. Founded in Canada, with a United States headquarters located in Boston, we are developing innovative solutions with the goal of reducing treatment burden and improving patient outcomes. To learn more about enGene visit our website: enGene.com. We are currently enrolling select patients with NMIBC in our LEGEND clinical trial. We have sites in the United States, Canada, Europe and the Asia-Pacific region. For more information, please visit TheLegendStudy.com.
Looking for a particular enGene employee's phone or email?
enGene Questions
The enGene annual revenue was $44.8 million in 2026.
Joan Connolly is the CTO of enGene.
79 people are employed at enGene.
enGene is based in Boston, Massachusetts.
The NAICS codes for enGene are [541990, 54199, 5419, 541, 54].
The SIC codes for enGene are [738, 73].
Top enGene Employees
-
Joan Connolly
Chief Technology Officer at enGene
New York, NY, US45+ -
Ryan Daws
Chief Financial Officer at enGene
Boston, MA, US25 -
Matthew Boyd
Chief Regulatory Officer at enGene
United States45 -
Jill Buck
Chief Development Officer at enGene
Andover, MA, US24 -
Kelly O'Hare
Vice President, Head of Quality at enGene
Natick, MA, US25 -
Joseph Davis
Vice President Information Technology at enGene
Melrose, MA, US25+ -
Christopher Klem
Vice President, Commercial Manufacturing at enGene
Frenchtown, NJ, US24 -
35+
-
Tara Place
Senior Vice President Human Resources at enGene
Boston, MA, US22
Related Companies
